Browse > Article
http://dx.doi.org/10.3340/jkns.2018.0031

Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes  

Michaeli, Orli (Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto)
Tabori, Uri (Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto)
Publication Information
Journal of Korean Neurosurgical Society / v.61, no.3, 2018 , pp. 319-332 More about this Journal
Abstract
Germline mutations in cancer causing genes result in high risk of developing cancer throughout life. These cancer predisposition syndromes (CPS) are especially prevalent in childhood brain tumors and impact both the patient's and other family members' survival. Knowledge of specific CPS may alter the management of the cancer, offer novel targeted therapies which may improve survival for these patients, and enables early detection of other malignancies. This review focuses on the role of CPS in pediatric high grade gliomas (PHGG), the deadliest group of childhood brain tumors. Genetic aspects and clinical features are depicted, allowing clinicians to identify and diagnose these syndromes. Challenges in the management of PHGG in the context of each CPS and the promise of innovative options of treatment and surveillance guidelines are discussed with the hope of improving outcome for individuals with these devastating syndromes.
Keywords
Cancer predisposition syndrome; High grade glioma; Li fraumeni syndrome; Constitutional mismatch repair deficiency; Neurofibromatosis 1; Surveillance;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, et al. : Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Canc Netw 10 : 939-942, 2012   DOI
2 Hersh JH; American Academy of Pediatrics Committee on Genetics : Health supervision for children with neurofibromatosis. Pediatrics 121 : 633-642, 2008   DOI
3 Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, et al. : Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5 : 104, 2010   DOI
4 Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, et al. : Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol 19 : 1047-1057, 2017   DOI
5 Huttner AJ, Kieran MW, Yao X, Cruz L, Ladner J, Quayle K, et al. : Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer 54 : 890-896, 2010
6 Lavoine N, Colas C, Muleris M, Bodo S, Duval A, Entz-Werle N, et al. : Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J Med Genet 52 : 770-778, 2015   DOI
7 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. : PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 : 2509-2520, 2015   DOI
8 Lemery S, Keegan P, Pazdur R : First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med 377 : 1409-1412, 2017   DOI
9 Hanahan D, Weinberg RA : Hallmarks of cancer: the next generation. Cell 144 : 646-674, 2011   DOI
10 Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. : A cancer family syndrome in twenty-four kindreds. Cancer Res 48 : 5358-5362, 1988
11 Malmer B, Adatto P, Armstrong G, Barnholtz-Sloan J, Bernstein JL, Claus E, et al. : GLIOGENE an international consortium to understand familial glioma. Cancer Epidemiol Biomarkers Prev 16 : 1730-1734, 2007   DOI
12 Mai P, Malkin D, Garber JE, Schiffman JD Weitzel JN, Strong LC, et al. : Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet 205 : 479-487, 2012   DOI
13 Malkin D : Li-Fraumeni syndrome. Genes Cancer 2 : 475-484, 2011   DOI
14 Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. : Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 : 1233-1238, 1990   DOI
15 Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, et al. : A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10 : 55-62, 2001   DOI
16 Ranger A, Szymczak A, Hammond RR, Zelcer S : Pediatric thalamic glioblastoma associated with Ollier disease (multiple enchondromatosis): a rare case of concurrence. J Neurosurg Pediatr 4 : 363-367, 2009   DOI
17 Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, et al. : Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging. JAMA Oncol 3 : 1634-1639, 2017   DOI
18 Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, et al. : Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23 : e68-e75, 2017   DOI
19 Reyes D, Prayson R : Glioblastoma in the setting of tuberous sclerosis. J Clin Neurosci 22 : 907-908, 2015   DOI
20 Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. : Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 : 124-128, 2015   DOI
21 Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, et al. : A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19 : 1135-1144, 2017   DOI
22 Bleeker FE, Hopman SMJ, Merks JHM, Aalfs CM, Hennekam RC : Brain tumors and syndromes in children. Neuropediatrics 45 : 137-161, 2014   DOI
23 Wimmer K, Rosenbaum T, Messiaen L : Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet 91 : 507-519, 2017   DOI
24 Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. : Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373 : 2336-2346, 2015   DOI
25 Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. : Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31 : 2927-35, 2013   DOI
26 Elmariah SB, Huse J, Mason B, Leroux P, Lustig RA : Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer. Breast J 12 : 470-474, 2006   DOI
27 Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, et al. : Exome sequencing identifies biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet 99 : 337-351, 2016   DOI
28 Albers AC, Gutmann DH : Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother 9 : 535-539, 2009   DOI
29 Amayiri N, Tabori U, Campbell B, Bakry D, Aronson M, Durno C, et al. : High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer 138 : 380-385, 2016   DOI
30 Gozali AE, Britt B, Shane L, Gonzalez I, Gilles F, McComb JG, et al. : Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer 58 : 905-909, 2012   DOI
31 Esteban-Jurado C, Gimenez-Zaragoza D, Munoz J, Franch-Exposito S, alvarez-Barona M, Ocana T, et al. : POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget 8 : 26732-26743, 2017
32 Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. : Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28 : 3061-3068, 2010   DOI
33 Ligtenberg MJL, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. : Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41 : 112-117, 2009   DOI
34 Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP : Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 96 : 238-242, 2001   DOI
35 Listernick R, Ferner RE, Liu GT, Gutmann DH : Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 61 : 189-198, 2007   DOI
36 Louis DN, Ohgaki H, Wiestler OD, Cavenee WK : WHO classification of tumours of the central nervous system, ed 4. Lyon : International Agency for Research on Cancer Publications, 2016
37 Grill J, Laithier V, Rodriguez D, Raquin MA, Pierre-Kahn A, Kalifa C : When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 159 : 692-696, 2000   DOI
38 Khatua S, Gutmann DH, Packer RJ : Neurofibromatosis type 1 and optic pathway glioma: molecular interplay and therapeutic insights. Pediatr Blood Cancer 65 : e26838, 2017
39 King A, Listernick R, Charrow J, Piersall L, Gutmann DH : Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet 122A : 95-99, 2003   DOI
40 Kinsella TJ : Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 15 : 1853-1859, 2009   DOI
41 Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J, et al. : Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Fam Cancer 16 : 433-440, 2017   DOI
42 Rosenfeld A, Listernick R, Charrow J, Goldman S : Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst 26 : 663-667, 2010   DOI
43 Rosser T, Packer RJ : Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol 17 : 630-637; discussion 646-651, 2002   DOI
44 Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, et al. : Regression of chemotherapy-resistant polymerase $\epsilon$ (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res 22 : 5682-5687, 2016   DOI
45 Varan A, Sen H, Aydin B, Yalcin B, Kutluk T, Akyuz C : Neurofibromatosis type 1 and malignancy in childhood. Clin Genet 89 : 341-345, 2016   DOI
46 Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, et al. : 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27 : e108-e109; author reply e110, 2009   DOI
47 Unger PD, Taff ML, Song S, Schwartz IS : Sudden death in a patient with Von Recklinghausen's neurofibromatosis. Am J Forensic Med Pathol 5 : 175-179, 1984   DOI
48 Uyttebroeck A, Legius E, Brock P, Van de Cassey W, Casaer P, Casteels-Van Daele M : Consecutive glioblastoma and B cell non-Hodgkin's lymphoma in a young child with von Recklinghausen's neurofibromatosis. Med Pediatr Oncol 24 : 46-49, 1995   DOI
49 Villani A, Malkin D, Tabori U : Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises. Curr Neurol Neurosci Rep 12 : 153-164, 2012   DOI
50 de Andrade KC, Mirabello L, Stewart DR, Karlins E, Koster R, Wang M, et al. : Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history. Hum Mutat 38 : 1723-1730, 2017   DOI
51 Bouffet E, Larouche V, Campbell BB, Merico D, De Borja R, Aronson M, et al. : Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34 : 2206-2211, 2016   DOI
52 Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. : Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33 : 2345-2352, 2015   DOI
53 Brodeur GM, Nichols KE, Plon SE, Schiffman JD, Malkin D : Pediatric cancer predisposition and surveillance: an overview, and a tribute to Alfred G. Knudson Jr. Clin Cancer Res 23 : e1-e5, 2017   DOI
54 Broekman ML, Risselada R, Engelen-Lee J, Spliet WG, Verweij BH : Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I. Case Rep Med 2009 : 757898, 2009
55 Distelmaier F, Fahsold R, Reifenberger G, Messing-Juenger M, Schaper J, Schneider DT, et al. : Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up. Child's Nerv Syst 23 : 343-347, 2007   DOI
56 Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, et al. : Comprehensive analysis of hypermutation in human cancer. Cell 171 : 1042-1056.e10, 2017   DOI
57 Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008   DOI
58 Cruz GR, Dias Oliveira I, Moraes L, Del Giudice Paniago M, De Seixas Alves MT, Capellano AM, et al. : Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. J Neurooncol 117 : 235-242, 2014   DOI
59 Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. : Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44 : 81-88, 2006   DOI
60 Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Schneider KW, et al. : Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res 23 : e46-e53, 2017   DOI
61 Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, et al. : Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14 : 790-797, 2012   DOI
62 Girardstein-Boccara L, Mari V, Met-Domestici M, Burel-Vandenbos F, Berthet P, Paquis P, et al. : Gliomas and BRCA genes mutations: fortuitous association or imputability? Bull Cancer 101 : 795-802, 2014
63 Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. : Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27 : 1250-1256, 2009   DOI
64 Goudie C, Coltin H, Witkowski L, Mourad S, Malkin D, Foulkes WD : The McGill Interactive Pediatric OncoGenetic Guidelines: an approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation. Pediatr Blood Cancer 64 : e26441, 2017   DOI
65 Jalali A, Amirian ES, Bainbridge MN, Armstrong GN, Liu Y, Tsavachidis S, et al. : Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene consortium. Sci Rep 5 : 8278, 2015   DOI
66 Jett K, Friedman JM : Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12 : 1-11, 2010
67 Kratz CP, Achatz MI, Brugieres L, Frebourg T, Garber JE, Greer MC, et al. : Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res 23 : e38-e45, 2017   DOI
68 Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H : Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150 : 1-13, 1997
69 Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, et al. : Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov 6 : 1230-1236, 2016   DOI
70 Knapke S, Nagarajan R, Correll J, Kent D, Burns K : Hereditary cancer risk assessment in a pediatric oncology follow-up clinic. Pediatr Blood Cancer 58 : 85-89, 2012   DOI
71 Kyritsis AP, Bondy ML, Rao JS, Sioka C : Inherited predisposition to glioma. Neuro Oncol 12 : 104-113, 2010   DOI
72 Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, et al. : Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361 : 1101-1102, 2003   DOI
73 McKeever K, Shepherd CW, Crawford H, Morrison PJ : An epidemiological, clinical and genetic survey of neurofibromatosis type 1 in children under sixteen years of age. Ulster Med J 77 : 160-163, 2008
74 Menor F, Marti-Bonmati L, Mulas F, Cortina H, Olague R : Imaging considerations of central nervous system manifestations in pediatric patients with neurofibromatosis type 1. Pediatr Radiol 21 : 389-394, 1991   DOI
75 Miaux Y, Guermazi A, Cornu P, Mokhtari K, Singer B, Chiras J, et al. : Highintensity lesion on T1-weighted MR images in neurofibromatosis type 1: a case of premalignant lesion. Acta Neurochir (Wien) 139 : 1085-1087, 1997   DOI
76 Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, et al. : Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA 314 : 913-925, 2015   DOI
77 Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, et al. : Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine. Eur J Cancer 84 : 290-303, 2017   DOI
78 Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, et al. : Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346 : 420-427, 2002   DOI
79 Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. : Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17 : 1295-1305, 2016   DOI
80 Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP, et al. : Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. J Clin Oncol 33 : 602-609, 2015   DOI
81 Bogler O, Su Huang HJ, Kleihues P, Cavenee WK : The p53 gene and its role in human brain tumors. Glia 15 : 308-327, 1995   DOI
82 Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, et al. : Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Fam Cancer, 2017 [Epub ahead of print]
83 Shete S, Lau CC, Houlston RS, Claus EB, Barnholtz-Sloan J, Lai R, et al. : Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the gliogene consortium. Cancer Res 71 : 7568-7575, 2011   DOI
84 Shibahara I, Sonoda Y, Suzuki H, Mayama A, Kanamori M, Saito R, et al. : Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations. Brain Tumor Pathol 1 : 10-18, 2018
85 Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. : Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet 47 : 257-262, 2015   DOI
86 Kaufman DK, Kimmel DW, Parisi JE, Michels VV : A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. Neurology 43 : 1728-1731, 1993   DOI
87 Dodgshun AJ, Sexton-Oates A, Saffery R, Sullivan MJ : Biallelic FANCD1/BRCA2 mutations predisposing to glioblastoma multiforme with multiple oncogenic amplifications. Cancer Genet 209 : 53-56, 2016   DOI
88 Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H : Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 117 : 653-656, 2009   DOI
89 Wimmer K, Etzler J : Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 124 : 105-122, 2008   DOI
90 Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. : Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium "Care for CMMRD" (C4CMMRD). J Med Genet 51 : 355-365, 2014   DOI
91 Dudley JC, Lin MT, Le DT, Eshleman JR : Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22 : 813-820, 2016   DOI
92 Durno C, Boland CR, Cohen S, Dominitz JA, Giardiello FM, Johnson DA, et al. : Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology 152 : 1605-1614, 2017   DOI
93 Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA : Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 56 : 7-15, 2011   DOI
94 Eisenstat DD, Pollack IF, Demers A, Sapp MV, Lambert P, Weisfeld-Adams JD, et al. : Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. J Neurooncol 121 : 573-581, 2015   DOI
95 Guillamo JS, Creange A, Kalifa C, Grill J, Rodriguez D, Doz F, et al. : Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 126(Pt 1) : 152-160, 2003   DOI
96 Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-1812, 2008   DOI
97 Gutmann DH, James CD, Poyhonen M, Louis DN, Ferner R, Guha A, et al. : Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology 61 : 1397-1400, 2003   DOI
98 Hakan T, Aker FV : Case report on a patient with neurofibromatosis type 1 and a frontal cystic glioblastoma. Neurol Neurochir Pol 42 : 362-365, 2008
99 Kandoth C, Mclellan MD, Vandin F, Ye K, Niu B, Lu C, et al. : Mutational landscape and significance across 12 major cancer types. Nature 502 : 333-339, 2013   DOI
100 Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. : Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63 : 6643-6650, 2003
101 Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, et al. : Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol 2 : 616-624, 2016   DOI
102 Patil S, Chamberlain RS : Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist 17 : 101-116, 2012   DOI
103 Scheffzek K, Ahmadian MR, Wiesmuller L, Kabsch W, Stege P, Schmitz F, et al. : Structural analysis of the GAP-related domain from neurofibromin and its implications. EMBO J 17 : 4313-4327, 1998   DOI
104 Schneider K, Zelley K, Nichols KE, Garber J : Li-Fraumeni syndrome in Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds) : $GeneReviews^{(R)}$. Seattle : University of Washington, 1993
105 Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, et al. : Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24 : 2570-2575, 2006   DOI
106 Sherborne AL, Lavergne V, Yu K, Lee L, Davidson PR, Mazor T, et al. : Somatic and germline TP53 alterations in second malignant neoplasms from pediatric cancer survivors. Clin Cancer Res 23 : 1852-1861, 2017   DOI
107 Tabori U, Laberge AM, Ellezam B, Carret AS : Cancer Predisposition in Children with Brain Tumors : Pediatric Neuro-oncology. New York : Springer New York, 2015, pp69-89
108 Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. : The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 131 : 803-820, 2016   DOI
109 Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, et al. : Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28 : 1345-1350, 2010   DOI
110 Tabori U, Hansford JR, Achatz MI, Kratz CP, Plon SE, Frebourg T, et al. : Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin Cancer Res 23 : e32-e37, 2017   DOI
111 Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, et al. : TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28 : 1995-2001, 2010   DOI
112 Andrianova MA, Chetan GK, Sibin MK, Mckee T, Merkler D, Narasinga RK, et al. : Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours. J Pathol 243 : 331-341, 2017   DOI
113 Aubrey BJ, Strasser A, Kelly GL : Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med 6 : a026062, 2016   DOI
114 Baas AF, Gabbett M, Rimac M, Kansikas M, Raphael M, Nievelstein RAJ, et al. : Agenesis of the corpus callosum and gray matter heterotopia in three patients with constitutional mismatch repair deficiency syndrome. Eur J Hum Genet 21 : 55-61, 2013   DOI
115 Bainbridge MN, Armstrong GN, Gramatges MM, Bertuch AA, Jhangiani SN, Doddapaneni H, et al. : Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst 107 : 384, 2015
116 Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. : Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer 50 : 987-996, 2014   DOI